CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 7 enrolled
Drug / intervention
Cholecalciferoldrug
Likely dose
Cholecalciferol 50,000 Unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00677534
NCT00677534N/ACompleted
CompareCT.gov

Exploring the Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease

University of Kansas·interventional·Posted May 14, 2008·Updated Apr 29, 2014

In Brief

A clinical study evaluating Cholecalciferol for End-Stage Renal Disease. Completed, enrolled 7 participants.

Detailed Summary

The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a potential contributor to the morbidity witnessed in patients with end-stage renal disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 14, 2008
Enrollment StartMay 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.1 years ago

Interventions

Cholecalciferoldrug

50,000 Units PO Twice weekly for 8 weeks